What Is TOFA? Fat Loss Without Muscle Loss (2026)

Quick answer: TOFA — the decades-old compound 5-tetradecyloxy-2-furoic acid — burned fat without significant muscle loss in obese mice, boosting energy expenditure by up to 18% with no change in diet or exercise, and it amplified the effects of GLP-1 drugs like semaglutide and tirzepatide when combined. For anyone following the TOFA weight loss headlines, this is the evidence rundown: the results come from a UC Berkeley study published in Science Advances on August 21, 2026, and they matter because they point at a completely different lever than appetite suppression. The catch: it’s a mouse study. No human data exists, TOFA is not a supplement you can buy, and any real-world availability is years away.

What Is TOFA?

TOFA (5-tetradecyloxy-2-furoic acid, CAS 54857-86-2) is a small-molecule compound first discovered in the 1970s. It belongs to a class known as ACC inhibitors, which work by reducing the body’s production of lipids — including cholesterol and triglycerides (ScienceDaily). Several ACC inhibitors have advanced into mid-stage clinical trials over the years, but none has been approved to treat metabolic disease.

The 2026 finding is that TOFA appears to do more than block lipid production. It also activates two nuclear receptors, PPARα and PPARδ, which turn on genes that help cells take up fat and burn it for energy.

TOFA is currently sold only as a research chemical, labeled “not for human or veterinary use.” No approved drug, no supplement product, and no human safety data exist behind it.

TOFA vs. “TOFA” Supplements (Tetradecylthioacetic Acid / TTA)

One naming trap has already produced confusion in online searches: there are two different compounds circulating as “TOFA.”

Name	Full chemical name	What it is	Status
TOFA (study compound)	5-tetradecyloxy-2-furoic acid	ACC inhibitor + PPARα/PPARδ activator studied in mice	Research chemical only; no human data
”TOFA” / TTA (supplement market)	tetradecylthioacetic acid	Unrelated omega-3 analog marketed as a fat burner	Supplement ingredient; not the study compound

If you see “TOFA” sold as a fat-burning supplement, you are almost certainly looking at TTA — not the compound from the Science Advances study. The study’s TOFA is not a fat burning supplement you can buy; the grey-market noise around the news spike is exactly where the two compounds get conflated.

How TOFA Burns Fat: A Different Lever Than GLP-1

The mechanistic headline from the study is that TOFA acts on energy expenditure, not appetite. Senior author Anders Näär, a professor of metabolic biology and nutrition at UC Berkeley, framed it as two levers:

“Body weight responds to two levers: taking in fewer calories, or spending more energy. GLP-1s work almost entirely on the first, so we went after the second.”

That is the core contrast with GLP-1 receptor agonists like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound), which work primarily by suppressing appetite and lowering energy intake. TOFA fat burn works through the second lever: the compound helps cells burn extra energy with no change in food intake or exercise (Berkeley News).

First author Justin Y. Lee, a postdoctoral researcher at UCSF with a Ph.D. from Berkeley, described the dual action this way:

“TOFA appears to engage a coordinated metabolic response. It is not simply blocking lipid synthesis. It is also activating energy expenditure pathways that may help the body handle excess lipid and glucose more effectively.”

What the 2026 Science Advances Study Found

The study, published as Lee et al., “A multi-functional oral small molecule targeting energy and lipid metabolism to treat obesity and related metabolic disorders,” Science Advances 12(34), 2026 (DOI: 10.1126/sciadv.aed3119), treated obese mice with TOFA. The mice did not change their diet or exercise habits. The key results:

• Up to 18% more energy burned — with no change in physical activity or body temperature.
• Fat loss without significant lean muscle loss — mice lost weight from fat while showing no significant reduction in lean muscle mass.
• Improved metabolic markers — better insulin sensitivity and glucose control, lower triglycerides, and improved features of fatty liver disease.
• No triglyceride rise — unlike some other ACC inhibitors, which have raised triglycerides in trials, TOFA did not.

The researchers also tested a two-compound combination — one lipid-production blocker plus one energy-expenditure booster — and found it less effective at improving overall metabolic health than TOFA alone.

The headline numbers (“up to 18% more energy”) are a reported ceiling, not a uniform effect across all animals. And critically, this is preclinical data in mice only — TOFA’s safety and effectiveness in humans remain unknown and will need to be evaluated in future studies (ScienceDaily).

Can TOFA Prevent GLP-1 Muscle Loss?

This is what the study’s combination arm was designed to test. GLP-1 drugs reduce appetite and food intake, but they may also contribute to nutritional deficiencies and loss of muscle. That matters because muscle plays a critical role in regulating blood sugar and maintaining metabolism — when people lose muscle along with fat, they can become weaker and find weight loss harder to maintain over time (NewsNation). The study combined TOFA with semaglutide and tirzepatide in mice and found larger improvements in body weight, glucose control, insulin levels, and triglycerides than either treatment produced on its own (Berkeley News; ScienceDaily).

Näär framed the combination as complementary, not competitive:

“In our combination experiments, TOFA worked additively or synergistically with the GLP-1 appetite-suppressing drugs, so we view it as complementary rather than as a replacement.”

For context on how GLP-1s shape body composition, see our GLP-1 and visceral fat breakdown, and for the 2026 regulatory picture, our coverage of the proposed 503B exclusions.

To be precise: this does not mean TOFA “prevents” GLP-1 muscle loss in humans. The mouse data show a profile worth studying — muscle-sparing fat loss plus additive benefit on top of GLP-1 treatment — but human trials would be required to test it.

When Will TOFA Be Available?

Not soon, and not as a supplement. The researchers have founded ReRx Therapeutics — supported by Nucleate and Berkeley SkyDeck — to move the work toward patients. The study’s conflict-of-interest statement discloses that Anders Näär, Justin Lee, and Prabha Ibrahim are co-founders or officers and equity holders of ReRx Therapeutics, which has optioned UC Berkeley intellectual property related to the work.

Realistic expectations:

• No human trials have been conducted. The compound has only been studied in animals, and its safety and efficacy in humans has yet to be tested (Berkeley News).
• No drug approval exists. It is not on any approval pathway; a clinical development program would be years out. Our FDA timeline tracker shows what an actual approval path looks like.
• Do not buy research chemicals. TOFA is sold for laboratory use only, explicitly “not for human or veterinary use.” Anyone searching “TOFA supplement” today is looking at grey-market noise built on the news spike — there is no such product, and the real compound is not one. Purchasing research chemicals to self-dose is neither legal for consumption nor evidence-based — see our guide to separating peptide science from hype.

The Bottom Line

• Promising mechanism: a single oral molecule that both blocks lipid production and activates fat-burning pathways — a genuinely different lever from appetite suppression.
• Real data, but mice only: up to 18% higher energy expenditure, fat loss with muscle preservation, and improved glucose, insulin, triglycerides, and liver markers — all in a preclinical mouse study with no human data.
• Complementary to GLP-1s, not a replacement: the combination arm showed additive improvements with semaglutide and tirzepatide.
• Not buyable today: research chemical only; no human safety data; any clinical path runs through a company that has not yet started trials.

For more on how metabolic compounds compare, see our MOTS-c evidence review and the full compounds directory. And for a standing rule of thumb when news like this hits, our Stanford-experts piece on peptide science versus hype is a good companion — as is the PeptidesBeat playbook for how to read this site’s evidence tiers.

Frequently Asked Questions

Can TOFA deliver weight loss without muscle loss? That is the hypothesis the study supports — in mice. TOFA produced fat loss with no significant loss of lean muscle mass, the profile people mean by “weight loss without muscle loss.” No human study has shown this effect.

Is TOFA a fat burning supplement? No. The TOFA in the Science Advances study (5-tetradecyloxy-2-furoic acid) is a research chemical, not a supplement. Products marketed as “TOFA” fat burners are typically a different compound — tetradecylthioacetic acid (TTA) — with no connection to this study.

Is TOFA the same as Ozempic? No. Ozempic (semaglutide) is an FDA-approved GLP-1 receptor agonist that suppresses appetite; TOFA is an unapproved experimental compound that increases energy expenditure. The mouse study tested them together and found additive benefits — complementary, not interchangeable.

Has TOFA been tested in humans? No. The published data is from mice only; its safety and effectiveness in humans have not been evaluated.

When could TOFA become available? The research team founded ReRx Therapeutics to carry the work forward, but no human trials have started. A realistic path to an approved product is measured in years, if the data supports it at all.

---

Disclaimer: This article is for educational purposes only and is not medical advice. PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments; we do not sell peptides, recommend dosing, or provide medical advice. TOFA is an experimental compound studied only in animals — it is not approved for human use, and research chemicals should never be consumed. Consult a licensed healthcare provider for any therapeutic question.

Sources:

1. UC Berkeley News, “A promising new weight-loss and diabetes treatment helps burn fat while keeping muscle” (Aug 21, 2026) — https://news.berkeley.edu/2026/08/21/a-promising-new-weight-loss-and-diabetes-treatment-helps-burn-fat-while-keeping-muscle/
2. Lee, J. Y., et al., “A multi-functional oral small molecule targeting energy and lipid metabolism to treat obesity and related metabolic disorders,” Science Advances 2026;12(34) — DOI: 10.1126/sciadv.aed3119 (https://www.science.org/doi/10.1126/sciadv.aed3119)
3. ScienceDaily, “Decades-old compound shows promise for weight loss without muscle loss” (Aug 23, 2026) — https://www.sciencedaily.com/releases/2026/08/260823014953.htm
4. NewsNation, “TOFA: Weight-loss compound burned fat and preserved muscle in study” (Aug 23, 2026) — https://www.newsnationnow.com/health/tofa-weight-loss-drug-burn-fat-preserve-muscle-study/